Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) shot up 8.6% during trading on Wednesday . The stock traded as high as $259.97 and last traded at $267.16. Approximately 758,392 shares traded hands during trading, a decline of 47% from the average session volume of 1,440,174 shares. The stock had previously closed at $246.11.
Analyst Ratings Changes
A number of brokerages recently commented on ALNY. HC Wainwright reiterated a "buy" rating and issued a $455.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday. Barclays reduced their price objective on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an "overweight" rating on the stock in a research note on Monday, August 3rd. Chardan Capital reiterated a "buy" rating and issued a $425.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, July 31st. Royal Bank Of Canada lowered their target price on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an "outperform" rating for the company in a research note on Friday, July 31st. Finally, Truist Financial dropped their target price on Alnylam Pharmaceuticals from $410.00 to $315.00 and set a "buy" rating for the company in a report on Tuesday, August 4th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $386.14.
Get Our Latest Research Report on Alnylam Pharmaceuticals
Alnylam Pharmaceuticals Price Performance
The business has a 50-day simple moving average of $260.86 and a 200 day simple moving average of $292.43. The firm has a market cap of $35.58 billion, a P/E ratio of 49.33 and a beta of 0.30. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05.
Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping analysts' consensus estimates of $1.63 by $0.21. The firm had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The business's quarterly revenue was up 66.9% compared to the same quarter last year. During the same period last year, the company earned ($0.51) EPS. On average, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Alnylam Pharmaceuticals
A number of institutional investors have recently bought and sold shares of ALNY. MV Capital Management Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $25,000. Caitong International Asset Management Co. Ltd bought a new stake in Alnylam Pharmaceuticals during the third quarter worth about $29,000. HM Payson & Co. bought a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $27,000. Golden State Wealth Management LLC grew its holdings in Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 36 shares during the period. Finally, Manchester Capital Management LLC grew its holdings in Alnylam Pharmaceuticals by 600.0% in the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 72 shares during the period. 92.97% of the stock is owned by institutional investors.
About Alnylam Pharmaceuticals
(
Get Free Report)
Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.
Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Alnylam Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.
While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
